Stockscreener 앱 받기
23.92
0.17%
0.04
시간 외 거래:
23.92
전일 마감가:
$23.88
열려 있는:
$23.88
하루 거래량:
1.32M
Relative Volume:
1.09
시가총액:
$2.94B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
20.27
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-1.12%
1개월 성능:
-5.15%
6개월 성능:
+20.87%
1년 성능:
+7.17%
1일 변동 폭
$23.64
$24.71
1주일 범위
$22.27
$25.14
52주 변동 폭
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.92 | 2.94B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Vanguard Group Inc. - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results - Insider Monkey
CPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc (CPRX) Q4 2025 Earnings Call Highli - GuruFocus
Catalyst Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y - Finviz
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com India
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Catalyst Pharma Q4 Net Income Slips; Announces FY26 Outlook - Nasdaq
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout - ChartMill
Catalyst Pharmaceuticals (CPRX) Net Margin Strength Reinforces Bullish Earnings Narrative - Sahm
Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT I - GuruFocus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat
Catalyst Pharmaceuticals Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook - TipRanks
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Revenue $152.6M, vs. FactSet Est of $142.7M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Adjusted EPS $0.68, vs. FactSet Est of $0.59 - marketscreener.com
CPRX | Catalyst Pharmaceutical Inc. FinancialsIncome Statement - Quiver Quantitative
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times
Catalyst Pharmaceuticals Reports Record Fourth Quarter and - GlobeNewswire
Catalyst Pharmaceuticals earnings on deck amid growth questions - Investing.com Nigeria
Catalyst Pharmaceuticals earnings on deck amid growth questions By Investing.com - Investing.com Canada
Catalyst: Q4 Financial Results Overview - Bitget
Catalyst Pharmaceuticals, Inc. (CPRX): Strong Buy Ratings and 43% Potential Upside Propel Investor Interest - DirectorsTalk Interviews
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Aug Volume: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Upgrade & Verified Chart Pattern Signals - baoquankhu1.vn
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Jupiter Asset Management Ltd. Sells 116,575 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
CEO Change: Is Catalyst Pharmaceuticals Inc a top pick in the sectorQuarterly Market Review & Safe Capital Preservation Plans - baoquankhu1.vn
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharma (CPRX) HR chief receives stock from RSU vesting - Stock Titan
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs (CPRX) - Seeking Alpha
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - Finviz
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for - Finviz
Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday - MarketBeat
Catalyst Pharmaceuticals (CPRX) Stock Analysis: 42% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews
Public Sector Pension Investment Board Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Aug Retail: Is Catalyst Pharmaceuticals Inc a momentum stock2025 Retail Activity & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc.’s growth already priced inTrade Exit Summary & Fast Gain Stock Trading Tips - mfd.ru
Is Catalyst Pharmaceuticals Inc. stock attractive for hedge fundsJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - mfd.ru
What is Catalyst Pharmaceuticals Inc. s 5 year growth outlookQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
Will Catalyst Pharmaceuticals Inc. benefit from government policy2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru
Block Trades: Is iShares Gold Trust impacted by rising ratesInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.71%
0.02%
자본화:
|
볼륨(24시간):